Navigation Links
Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
Date:9/24/2009

FRAZER, Pa., Sept. 24 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced the U.S. Food and Drug Administration (FDA) has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV], which was filed in June of this year. The FDA decision on approval of NUVIGIL as a treatment for improving wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel is expected by December 29, 2009. There currently is no FDA-approved treatment for jet lag disorder.

The NUVIGIL sNDA is based on data from a Phase III pivotal study that evaluated the efficacy and safety of NUVIGIL (50 or 150 mg/day) in 427 healthy adults over three days during travel from the United States to Europe. These data were presented earlier this year at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies.

About NUVIGIL

NUVIGIL, the longer-lasting isomer of modafinil, was launched in the United States in June 2009 and is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work sleep disorder, also known as shift work disorder (SWD), and narcolepsy. NUVIGIL is not approved as a treatment for jet lag disorder or its associated symptoms. The NUVIGIL label includes a bolded warning for serious or life-threatening rash, including Stevens-Johnson syndrome, that has been reported in adults and children taking modafinil, a racemic mixture of S and R modafinil (the latter is armodafinil, the active ingredient in NUVIGIL). NUVIGIL is not approved for use in pediatric patients for any indication.

The most common adverse events in controlled clinical trials (five pe
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
2. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
3. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
4. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
8. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Pres. Clinton Announces Commitment From Inter-American Development Bank, Global Network for Neglected Tropical Diseases, and Pan American Health Organization to Mobilize $30 Million to Fight NTDs in the Americas at CGI Conference
11. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015   Sentrian , the ... preventable hospitalization, recently received confirmation from the Food ... Intelligence (RPI) solution meets the definition of a ... exercise "Enforcement Discretion." The designation ... further FDA regulatory requirements at this time" and ...
(Date:7/30/2015)... 30, 2015 What can be ... areas are going to grow at the fastest rates? ... revenues to 2025, assessing data, trends, opportunities and prospects ... 176 tables, charts, and graphs. Discover the most lucrative ... Our new study lets you assess forecasted sales at ...
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
Breaking Medicine Technology:FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ... develops and commercializes prescription,drugs for the treatment ... announced that it has begun enrollment for ... trial evaluating,CPP-109 for the treatment of patients ...
... Company,s End-of-Phase II Meeting with FDA Set for ... TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today ... Meeting of the American Headache Society showed that, ... pain relief at two,hours, the company,s lead AMPA/kainate-type ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction 2Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction 3Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction 4Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 2Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 3
(Date:7/31/2015)... ... July 31, 2015 , ... ... a Balloon Sinuplasty website to inform potential Nashville area sinus sufferers ... can be used to determine if someone is a good candidate for Balloon ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error ... **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, ... helping drug, biologic and device firms reduce manufacturing errors by 50 percent or ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... announces I am Fine, an app invention that can help people during emergencies. ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Currently, there ...
(Date:7/30/2015)... ... July 30, 2015 , ... In an effort to provide the twenty ... making a change in his practice. , The decision will also allow him to ... Aggarwal will be transferring his in-patient admissions to the hospitalists at East Liverpool City ...
(Date:7/30/2015)... ... 30, 2015 , ... In a meaningful ritual intended to symbolize a final ... Center have created an addiction graveyard. Sharing this with the public comes at a ... Rocky Hudson . Hudson (1945-2015) fell in love with the desert when he moved ...
Breaking Medicine News(10 mins):Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
... Inc., a leader in,manufacturing execution systems (MES) for ... to START-IT magazine,s START-IT 125 list., The ... and editorial advisors,of START-IT magazine to recognize the ... Visiprise,s flagship solution, Visiprise Manufacturing, is a,manufacturing ...
... Says Amazon Watch, SAN FRANCISCO, March 26 ... urged to impose a "substantial" sanction on,Chevron for ... resulting from a class-action environmental lawsuit in the,Ecuadorian ... Christopher Cox, environmental group Amazon,Watch said Chevron had ...
... in Physician and Nurse Training Needed, Experts Say, ... Physician and,Nurse Supply, an independent group of healthcare ... on the White House to convene a,special conference ... "Access to healthcare services cannot be maintained, ...
... Good for You Food Meets Great Taste, CHICAGO, ... to,incorporate whole grains into their daily diet without sacrificing ... pasta maker,introduces Barilla Whole Grain. Made with 51 percent ... excellent natural source of fiber,delivering three times the fiber ...
... 26 WPCS International,Incorporated (Nasdaq: WPCS ... specialty communication systems and wireless infrastructure, has,announced ... awarded approximately,$12 million in new contracts., ... for The University of,Connecticut, The Mashantucket Pequot ...
... Spanish . , Ignacio Lpez-Goi and David ... of the University of Navarra, have launched a new ... bacteria, which is the causative agent for brucellosis, also ... analysis kit, sold under the brand name Bruce-ladder, and ...
Cached Medicine News:Health News:Visiprise Named One of the Top Manufacturing Technology Providers 2Health News:SEC Complaint Lodged Against Chevron for Hiding $10 Billion Liability in Ecuador 2Health News:Council Calls on White House to Convene Conference on Physician and Nurse Supply 2Health News:Barilla(R) Whole Grain Makes Healthy Eating Easy 2Health News:WPCS Announces $12 Million in New Projects 2Health News:A product for the detection and characterization of brucellosis launched at University of Navarra 2
... Continuing a tradition of progressive centrifuge ... CL3 series. The Centra-CL3 and Centra-CL3R (refrigerated) ... todays laboratory., Quality Control Over Sample ... and lock up to 99 protocols and ...
Inquire...
... Rotor has a standard 1.5ml rotor and 6 ... Easy operation (no switches to mess with). Simply ... the plastic tab to open. Starts and stops ... 2000 x g. Only five inches in diameter. ...
Inquire...
Medicine Products: